• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconRoche

Roche

Roche and Nestlé fear talent crunch as Switzerland puts population cap to the polls
Europe
Roche and Nestlé fear talent crunch as Switzerland puts population cap to the polls
By Sam ForsdickJune 12, 2026
A man walks next to a sign for the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Before US President Donald Trump postponed a range of imminent tariffs, Switzerland was facing a daunting 31% levy on most Swiss goods to imported to the United States, a higher rate than would have been imposed on European Union countries. Such a tariff would've been high damaging to iconic Swiss industries like chocolate and watchmaking. The reprieve will provide breathing room for Swiss officials looking to negotiate a deal with the US, although Swiss goods will still face a 10% tariff in the meantime, and the fate of a potential separate tariff on pharmaceuticals is unknown.
Health
Swiss drugmaker Roche leans into Trump tariff formula with $50 billion promise to invest in U.S.
By Ryan HoggApril 22, 2025
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
Retail
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
By Paula Doenecke, Naomi Kresge and BloombergMarch 12, 2025
A young woman undergoes a brain scan.
Health
Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug
By Lindsey LeakeFebruary 6, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Roche stock is falling after report its Wegovy challenger is causing patients to vomit
Health
Roche stock is falling after report its Wegovy challenger is causing patients to vomit
By Naomi Kresge and BloombergSeptember 12, 2024
Thomas Schinecker, chief executive officer of Roche
Finance
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
By Prarthana PrakashJuly 29, 2024
Thomas Schinecker, CEO of Roche Holding.
Retail
An obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value
By Naomi Kresge, Lisa Pham and BloombergJuly 23, 2024
Thomas Schinecker, chief executive officer of Roche Holding
Finance
Switzerland shouldn’t follow Europe’s lead on tax, says Roche CEO. Instead, it must compete with ‘Dubai, China and India’
By Paula Doenecke and BloombergMay 14, 2024
Pascal Soriot, chief executive officer of Astrazeneca Plc, arrives at the CEO council at the Great Hall of the People in Beijing, Chin
Success
Major investors say AstraZeneca boss is ‘massively underpaid’ on $21.5 million salary, despite earning more than double Novo Nordisk’s CEO
By Ryan HoggApril 10, 2024
Stock traders from various companies work in five circular and one semi-circular trading floor at the Frankfurt Stock Exchange.
Finance
Meet Europe’s answer to the ‘Magnificent 7’—the high-flying ‘Granolas’ that Goldman Sachs is betting will prosper in the continent’s flatlining economy
By Ryan HoggMarch 3, 2024
Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
Finance
Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
By Paula Doenecke and BloombergDecember 4, 2023
Drug trial
Health
Roche is using AI to find the hardest-to-find lung cancer patients, with a potential blockbuster drug on the line
By Naomi Kresge and BloombergOctober 22, 2023
Why a biotech firm’s market value jumped from $3 million to $130 million in a day and is still way up from its ‘almost unfathomably low valuation’
Health
Why a biotech firm’s market value jumped from $3 million to $130 million in a day and is still way up from its ‘almost unfathomably low valuation’
By Angel Adegbesan and BloombergOctober 13, 2023
Market trader recession
Europe
A top Wall Street strategist changes his tune and says the U.S. can now avoid a recession
By Sophie MellorJune 20, 2022
1
  • 1
  • 2
  • 3
  • 4
4
Most Popular
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Personal Finance
Current price of oil as of July 1, 2026placeholder alt text
By Joseph HostetlerJuly 1, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.